Linked Data API

Show Search Form

Search Results

1701024
registered interest false more like this
date less than 2024-04-15more like thisremove minimum value filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Incontinence: Health Services more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if she will make it her policy to make an assessment of the potential impact of any proposed amendments to Part IX of the Drug Tariff on (a) patients with continence care needs, (b) continence care services, (c) the range of continence devices available to clinicians and patients and (d) new product development and innovation in medical devices in the continence sector. more like this
tabling member constituency Stockport more like this
tabling member printed
Navendu Mishra more like this
uin 21863 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-18more like thismore than 2024-04-18
answer text <p>Part IX will remain a list of devices available to be prescribed in the community, via the FP10 prescription route. The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on were intended to increase meaningful choice, not to decrease the choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers, which can support small and medium sized businesses in entering the market.</p><p>The consultation response on the proposed amendments to Part IX is expected to be released in May 2024, which will outline the Government’s response. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and National Health Service organisations. We are aware that there are some very good devices in use, relied upon by clinicians and patients.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-04-18T09:34:23.493Zmore like thismore than 2024-04-18T09:34:23.493Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4811
label Biography information for Navendu Mishra more like this